Sorafenib (SOR) is the only systemic agent known to improve survival for hepatocellular
carcinoma (HCC). However, SOR prolongs survival by less than 3 months and does not alter …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer with poor
prognosis. The incidence of HCC and HCC-related deaths have increased over the last …

Background/Aim: We report the outcomes of sorafenib therapy for advanced hepatocellular
carcinoma (HCC) in our Department. Patients and Methods: Thirty-eight patients with …

BACKGROUND: Sorafenib is currently approved for advanced hepatocellular carcinoma
(HCC) and is presently being studied as an adjuvant treatment for HCC following resection …

BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment
Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival …

Accumulated understanding of the molecular pathways regulating cancer progression has
led to the development of novel targeted therapies. Hepatocellular carcinoma (HCC) …

Background: Sorafenib is the first molecular-targeted agent that is effective for advanced
hepatocellular carcinoma (HCC), with prolongation of survival. However, a complete …

Sorafenib is a multikinase inhibitor for the treatment of hepatocellular carcinoma. However,
most patients who initially respond to sorafenib become refractory. In a previous study, we …

Hepatocellular Carcinoma: A Prospective Multicenter Study in Italy” by Iavarone et al. was
published in this journal. 1 To date, the conclusions of this article continue to stimulate …

Currently, only one drug, sorafenib, is FDA approved for the treatment of advanced
hepatocellular carcinoma (HCC), achieving modest objective response rates while still …